Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends
| Autor: | Nicolas André, Odile Minckes, Marie-Laure Couec, Franck Bourdeaut, Perrine Marec Bérard, Estelle Thebaud, Pierre Leblond, Nadège Corradini, Isabelle Aerts, Xavier Rialland |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Ependymoma Oncology medicine.medical_specialty Adolescent Bevacizumab medicine.medical_treatment Antibodies Monoclonal Humanized Irinotecan chemistry.chemical_compound Internal medicine Glioma Antineoplastic Combined Chemotherapy Protocols medicine Humans Child Retrospective Studies Chemotherapy Proteinuria Brain Neoplasms business.industry Infant Hematology medicine.disease Surgery Vascular endothelial growth factor chemistry Child Preschool Concomitant Pediatrics Perinatology and Child Health Camptothecin Female medicine.symptom business medicine.drug |
| Zdroj: | Pediatric Blood & Cancer. 59:34-38 |
| ISSN: | 1545-5009 |
| Popis: | Background Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, has proven efficacy in some adult tumors; it is now proposed as a new therapeutic strategy for refractory or recurrent brain tumors in some children, either alone or combinated. Procedure We retrospectively analyzed 28 children who received bevacizumab on a compassionate basis for refractory or recurrent brain tumors between June 2007 and August 2010 in 7 French centers. Among them, 12 had high-grade gliomas, 7 low-grade gliomas, 4 ependymomas, 2 primitive neurectodermal tumors, 3 neuroglial tumors. The median age at start of bevacizumab was 11.0 years. Bevacizumab was administered at 5–10 mg/kg every 2 weeks, with concomitant chemotherapy for 27 patients. Results Bevacizumab was used in combination with irinotecan in 27 patients. Bevacizumab-related toxicity was mild. Toxicities reported were grade I–II hypertension (n = 4), proteinuria (n = 1), lymphopenia (n = 2), wound healing delay (n = 2). Whereas tumor reduction could be observed in 6:7 patients with low-grade gliomas, no efficacy could be documented in patients with high-grade glioma, nor PNET nor ependymoma. Conclusion Bevacizumab-related acute toxicity appears to be low in children, even in combination with irinotecan. Further prospective trials are required to confirm the hypothetical efficacy of bevacizumab and to assess the risk of long-term toxicity especially in the youngest children. Pediatr Blood Cancer 2012; 59: 34–38. © 2012 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text